NextCell Pharma AB (65G) Ratios
0 Followers
NextCell Pharma AB Ratios
DE:65G's free cash flow for Q3 2026 was kr-11.59M. For the 2026 fiscal year, DE:65G's free cash flow was decreased by kr-175.09K and operating cash flow was kr-11.41M. See a summary of the company’s cash flow.
| Ratios | Aug 25 | Aug 24 | Aug 23 | Aug 22 | Aug 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.02 | 6.14 | 6.67 | 15.40 | 37.02 |
| Quick Ratio | 9.92 | 6.09 | 6.67 | 15.29 | 37.02 |
| Cash Ratio | 7.13 | 4.74 | 4.96 | 14.01 | 35.17 |
| Solvency Ratio | -3.15 | -2.99 | -3.00 | -3.69 | -4.36 |
| Operating Cash Flow Ratio | -7.16 | -3.83 | -4.35 | -4.81 | -6.46 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | kr 44.05M | kr 46.94M | kr 54.17M | kr 97.64M | kr 140.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.16 | 1.20 | 1.17 | 1.08 | 1.04 |
| Debt Service Coverage Ratio | -12554.08 | -30202.76 | -13998.49 | -2485.76 | -3197.98 |
| Interest Coverage Ratio | -13802.15 | -31814.38 | -14581.13 | -2588.99 | -3277.57 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 1.19 | 1.14 | 1.27 | 2.85 | 5.75 |
| Profitability Margins | |||||
| Gross Profit Margin | -327.98% | -42.74% | -8.75% | -398.31% | -371.36% |
| EBIT Margin | -321.31% | -393.45% | -393.62% | -618.04% | -627.53% |
| EBITDA Margin | -298.32% | -384.31% | -389.22% | -610.10% | -618.88% |
| Operating Profit Margin | -327.98% | -404.81% | -405.42% | -626.68% | -634.48% |
| Pretax Profit Margin | -321.31% | -393.45% | -393.65% | -618.28% | -627.73% |
| Net Profit Margin | -321.31% | -393.45% | -393.65% | -609.88% | -627.92% |
| Continuous Operations Profit Margin | -321.31% | -393.45% | -393.65% | -618.28% | -627.73% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 98.64% | 100.03% |
| EBT Per EBIT | 97.97% | 97.19% | 97.10% | 98.66% | 98.94% |
| Return on Assets (ROA) | -45.80% | -51.62% | -44.82% | -27.34% | -15.78% |
| Return on Equity (ROE) | -52.94% | -62.07% | -52.57% | -29.50% | -16.37% |
| Return on Capital Employed (ROCE) | -50.31% | -60.45% | -52.07% | -29.75% | -16.37% |
| Return on Invested Capital (ROIC) | -50.31% | -60.45% | -52.07% | -29.35% | -16.37% |
| Return on Tangible Assets | -45.80% | -51.62% | -44.82% | -27.34% | -15.78% |
| Earnings Yield | -38.98% | -45.20% | -16.08% | -7.81% | -2.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.72 | 0.80 | 0.00 | 0.63 | 0.54 |
| Payables Turnover | 17.41 | 2.47 | 12.34 | 14.47 | 14.39 |
| Inventory Turnover | 85.85 | 27.92 | 0.00 | 36.31 | 0.00 |
| Fixed Asset Turnover | 0.76 | 0.84 | 0.75 | 0.56 | 1.35 |
| Asset Turnover | 0.14 | 0.13 | 0.11 | 0.04 | 0.03 |
| Working Capital Turnover Ratio | 0.22 | 0.20 | 0.13 | 0.05 | 0.05 |
| Cash Conversion Cycle | 488.21 | 320.27 | -29.59 | 564.15 | 656.88 |
| Days of Sales Outstanding | 504.92 | 454.80 | 0.00 | 579.32 | 682.24 |
| Days of Inventory Outstanding | 4.25 | 13.07 | 0.00 | 10.05 | 0.00 |
| Days of Payables Outstanding | 20.96 | 147.60 | 29.59 | 25.22 | 25.37 |
| Operating Cycle | 509.17 | 467.88 | 0.00 | 589.38 | 682.24 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.51 | -0.52 | -0.64 | -0.48 | -0.42 |
| Free Cash Flow Per Share | -0.56 | -0.52 | -0.70 | -0.59 | -0.43 |
| Dividend Paid and CapEx Coverage Ratio | -9.30 | -455.59 | -10.69 | -4.39 | -35.23 |
| Capital Expenditure Coverage Ratio | -9.30 | -455.59 | -10.69 | -4.39 | -35.23 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -3.55 | -3.54 | -4.33 | -5.96 | -6.54 |
| Free Cash Flow Yield | -47.74% | -40.79% | -19.36% | -9.37% | -2.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.57 | -2.21 | -6.22 | -12.81 | -35.90 |
| Price-to-Sales (P/S) Ratio | 8.24 | 8.70 | 24.48 | 78.12 | 225.44 |
| Price-to-Book (P/B) Ratio | 1.36 | 1.37 | 3.27 | 3.78 | 5.88 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.09 | -2.45 | -5.17 | -10.67 | -33.53 |
| Price-to-Operating Cash Flow Ratio | -2.32 | -2.46 | -5.65 | -13.11 | -34.48 |
| Price-to-Earnings Growth (PEG) Ratio | 0.13 | 1.28 | -0.42 | -0.52 | 3.99 |
| Enterprise Value Multiple | -1.58 | -1.12 | -5.02 | -9.96 | -30.68 |
| Enterprise Value | 51.44M | 46.04M | 197.51M | 339.50M | 742.78M |
| EV to EBITDA | -1.58 | -1.12 | -5.02 | -9.96 | -30.68 |
| EV to Sales | 4.70 | 4.32 | 19.53 | 60.75 | 189.87 |
| EV to Free Cash Flow | -1.20 | -1.22 | -4.12 | -8.30 | -28.24 |
| EV to Operating Cash Flow | -1.32 | -1.22 | -4.51 | -10.19 | -29.04 |
| Tangible Book Value Per Share | 0.87 | 0.92 | 1.10 | 1.68 | 2.47 |
| Shareholders’ Equity Per Share | 0.87 | 0.92 | 1.10 | 1.68 | 2.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.01 | -0.00 |
| Revenue Per Share | 0.14 | 0.15 | 0.15 | 0.08 | 0.06 |
| Net Income Per Share | -0.46 | -0.57 | -0.58 | -0.50 | -0.40 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.99 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 2.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.11 | 0.90 | 1.07 | 0.95 | 1.03 |
Currency in SEK
